TopgOptions

ARDS upside potential

NASDAQ:ARDS   None
ARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19.

And the Market Cap is only 23.892Mil.

In my opinion this stock can double in trice anytime, their pipeline is highly undervalued.

면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.